La cadena de opciones muestra datos clave de las opciones de acciones de Protalix BioTherapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Protalix BioTherapeutics..

Protalix BioTherapeutics (AMEX:PLX) Bolsa, Cadena de Opciones

Protalix BioTherapeutics

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics Inc

Plexus Corp

Piolax Inc

Pluxee NV

PLx Pharma Inc

PLx Pharma Winddown Corp

Press Releases

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Earnings

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Biotech

Events

Protalix BioTherapeutics to Present at Investor Summit Virtual

Health Care

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Adicet Bio

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Anika Therapeutics

Anixa Biosciences

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atossa Therapeutics

Compugen

Climb Bio

Cardiff Oncology

Citius Oncology

Elicio Therapeutics

Fate Therapeutics

Forte Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Seres Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Nuvectis Pharma

TScan Therapeutics

Instil Bio

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tevogen Bio Holdings

HC Wainwright & Co.

Comments

Protalix BioTherapeutics

Protalix BioTherapeutics (PLX) Opciones

Protalix BioTherapeutics (AMEX:PLX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL